Company intelligence / Profile preview

Beijing Xuze Pharmaceutical Technology

Ownership: Private
Development stage: Other

Overview

Beijing Xuze Pharmaceutical Technology develops and licenses biomedical products. Its resources include a Phase 4 clinical trial evaluating a carbomer birth canal gel for efficacy and safety in natural delivery, and completion of Phase 1 pharmacokinetic studies for lansoprazole oral formulations in Chinese volunteers. The company is involved in formulation and preparation technology, with at least one patent for injectable oxiracetam solutions.[5][7][9]

Therapeutic areas: Women's HealthGastroenterology
Modalities: Small moleculePolymer-based topical gel
Industry: Biotech

Partnerships

Chengdu Innovo Pharmaceutical

Beyond the preview

Go deeper on Beijing Xuze Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Xuze Pharmaceutical Technology.